Actively Recruiting
Evaluating Safety and Effectiveness of Anti-BCMA CAR-T Cell Therapy in Adults With Relapsed or Refractory Multiple Myeloma
Led by Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology · Updated on 2026-10-16
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of anti-BCMA CAR-T cell immunotherapy for adults with relapsed or refractory multiple myeloma. This study includes both Phase I and Phase II to explore safety concerns such as cytokine release syndrome and infections, as well as the treatments overall response and survival rates. The trial is sponsored by the Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology and focuses on patients resistant to prior therapies. Participants receive locally manufactured, second-generation autologous humanized anti-BCMA CAR-T cells. The treatment process involves leukapheresis to collect T cells, followed by a lymphodepleting chemotherapy regimen with fludarabine and cyclophosphamide before receiving a single CAR-T cell infusion. The dose ranges from 50 million to 250 million cells. The study evaluates pharmacokinetics and monitors for adverse events during both phases. During the trial, participants undergo monitoring for safety within one month post-infusion and evaluation of treatment response up to twelve months. Additional assessments include progression-free survival, overall survival, and duration of response over three years. Researchers track CAR-T cell expansion and peak levels. The total study duration extends until 2030, with regular clinical visits and laboratory evaluations throughout the follow-up period.
CONDITIONS
Brief Title
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Research Team
M
Mikhail Uss, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here